Clinical and demographic data of the patient sample (participants and dropouts are shown separately) and results of psychosocial assessment using the Distress Thermometer, the EORTC-QLQ-C30 and EORTC-QLQ-BN20, and the SCNS SF34-G at t1 are displayed
| . | Total study sample (t1) n = 173 (100%) . | Patients with complete follow-up (t1 and t2) n = 141 (82%) . | Patients without follow-up (no t2) n = 32 (19%) . | |
|---|---|---|---|---|
| deceased n = 14 (8%) . | dropout (non-death-related) n = 18 (10%) . | |||
| Time since t1 in months . | . | . | . | . |
| Mean (SD, Min–Max) | 5.34 (2.5, 1.4–13.8) | 5.31 (2.6, 1.4–1.3) | 5.62 (3.7, 1.6–13.8) | 5.03 (0.0, 5.0–5.0) |
| Median, Q1–Q3 | 5.0 (3.2–6.2) | 4.8 (3.1–6.7) | 3.7 (2.9–9.0) | 5.0 (5.0–5.0) |
| Age in years* | ||||
| Mean (SD, Min–Max) | 51 (14, 21–78) | 50 (14, 21–78) | 62 (12, 37–76) | 51 (13, 29–75) |
| Sex n (%) | ||||
| male | 92 (53) | 72 (51) | 8 (57) | 12 (67) |
| female | 81 (47) | 69 (49) | 6 (43) | 6 (33) |
| Living situation*, n (%) | ||||
| single | 39 (22) | 30 (21) | 2 (14) | 7 (39) |
| in relationship | 124 (72) | 102 (72) | 12 (86) | 10 (56) |
| unknown | 10 (7) | 9 (7) | - | 1 (5) |
| WHO grade*, n (%) | ||||
| LGG (WHO I and II) | 32 (19) | 26 (18) | - | 6 (33) |
| HGG (WHO III and IV) | 141 (81) | 115 (82) | 14 (100) | 12 (67) |
| Tumor localization I*, n (%) | ||||
| frontal | 75 (43) | 68 (48) | 3 (21) | 4 (22) |
| temporal | 48 (28) | 38 (27) | 7 (50) | 3 (17) |
| parietal | 23 (13) | 18 (13) | 3 (21) | 2 (11) |
| occipital | 12 (7) | 6 (4) | 1 (7) | 5 (28) |
| other | 15 (9) | 11 (8) | - | 4 (22) |
| Tumor localization II *, n (%) | ||||
| eloquent | 87 (50) | 71 (50) | 8 (57) | 8 (44) |
| non eloquent | 85 (49) | 69 (49) | 6 (43) | 10 (56) |
| n.a. | 1 (1) | 1 (1) | - | - |
| Extent of resection, n (%) | ||||
| subtotal resection/biopsy | 68 (39) | 55 (39) | 10 (71) | 3 (17) |
| complete resection | 102 (59) | 83 (59) | 4 (29) | 15 (83) |
| n.a. | 3 (2) | 3 (2) | - | - |
| Ongoing chemotherapy*, n (%) | ||||
| yes | 63 (36) | 44 (31) | 11 (79) | 8 (44) |
| no | 110 (64) | 97 (69) | 3 (21) | 10 (56) |
| Surgery for recurrent tumor*, n (%) | ||||
| yes | 56 (32) | 45 (32) | 6 (43) | 5 (28) |
| no | 117 (68) | 96 (68) | 8 (57) | 13 (72) |
| Karnofsky Peformance Status (KPS)* | ||||
| Median (SD, range) | 90 (40–100) | 90 (40–100) | 70 (60–90) | 90 (10–100) |
| KPS < 70, n (%) | 18 (10.4) | 7 (5.0) | 4 (22.2) | 7 (50.0) |
| KPS ≥ 70, n (%) | 151 (87.3) | 130 (92.2) | 14 (77.8) | 7 (50.0) |
| n.a. | 4 (2.3) | 4 (2.8) | - | - |
| Time since diagnosis in months* | ||||
| Mean (SD, range) | 46 (49, 2–278) | 52 (54, 28–279) | 31 (41, 2–125) | 60 (55, 4–173) |
| Median, Q1–Q3 | 34 (10–70) | 35 (14–69) | 13 (8–34) | 47 (7–95) |
| < 3 years, n (%) | 89 (51) | 71 (50) | 11 (79) | 7 (39) |
| ≥ 3 years, n (%) | 76 (44) | 65 (46) | 3 (21) | 8 (44) |
| n.a. | 8 (5) | 5 (4) | - | 3 (17) |
| Value of Distress Thermometer* | ||||
| Mean (SD, range) | 4.6 (2.7; 0.0–10.0) | 4.6 (2.8; 0.0–10.0) | 5.2 (2.3; 0.0–9.0) | 4.4 (2.5; 0.0–8.0) |
| < 6 (n, %) | 109 (63) | 88 (62) | 9 (64) | 12 (67) |
| ≥ 6 (n, %) | 57 (33) | 46 (33) | 5 (36) | 6 (33) |
| n.a. | 7 (4) | 7 (5) | - | - |
| Selected EORTC-QLQ-C30 and EORTC-QLQ-BN20 Scores*, Mean (SD) | ||||
| C30 Global Health Status/QoL | 61.0 (22.7) | 62.1 (23.0) | 54.2 (22.3) | 57.9 (20.9) |
| C30 Physical functioning | 74.7 (25.6) | 77.1 (24.8) | 56.2 (28.8) | 70.4 (24.2) |
| C30 Emotional functioning | 59.4 (27.4) | 59.3 (28.2) | 59.5 (23.3) | 60.3 (24.9) |
| C30 Cognitive functioning | 63.0 (32.5) | 64.0 (32.5) | 50.0 (33.3) | 65.7 (31.4) |
| BN20 Future uncertainty | 39.3 (29.2) | 38.8 (29.9) | 38.8 (25.9) | 43.8 (27.3) |
| BN20 Motor dysfunction | 25.0 (27.2) | 21.6 (26.1) | 42.9 (31.4) | 36.4 (25.2) |
| SCNS-SF34G Scores* | ||||
| Physical and daily living needs Mean (SD) | 19.2 (21.4; 0.0–83.3) | 19.8 (22.7) | 14.7 (13.9) | 18.1 (14.8) |
| Median (Q1 – Q3) | 12.5 (0.0–25.0) | 12.5 (0–29.2) | 12.5 (4.2–22.9) | 16.7 (7.3–26.0) |
| Psychological needs Mean (SD) | 26.9 (27.8; 0.0–95.0) | 27.4 (28.6) | 25.7 (27.9) | 24.3 (22.8) |
| Median (Q1 – Q3) | 17.5 (5.0–45.0) | 17.5 (5.0–46.3) | 12.5 (1.3–48.8) | 11.3 (5.0–45.0) |
| Patient care and support needs Mean (SD) | 10.5 (19.1; 0.0–93.8) | 10.2 (18.3) | 10.7 (24.3) | 13.0 (21.7) |
| Median (Q1 – Q3) | 0.0 (0.0–12.5) | 0.0 (0–12.5) | 0.0 (0.0–10.9) | 0.0 (0.0–21.9) |
| Health system and information needs Mean (SD) | 22.1 (27.3; 0.0–100.0) | 22.2 (27.4) | 13.5 (19.8) | 27.0 (30.7) |
| Median (Q1 – Q3) | 11.4 (0.0–36.4) | 11.0 (0.0–36.4) | 4.5 (2.3–19.3) | 15.9 (0.0–53.3) |
| Sexuality needs Mean (SD) | 13.4 (21.8; 0.0–100.0) | 14.6 (22.5) | 5.8 (14.2) | 9.8 (21.1) |
| Median (Q1 – Q3) | 0.0 (0.0–16.7) | 0.0 (0.0–25.0) | 0.0 (0.0–4.2) | 0.0 (0.0–12.5) |
| . | Total study sample (t1) n = 173 (100%) . | Patients with complete follow-up (t1 and t2) n = 141 (82%) . | Patients without follow-up (no t2) n = 32 (19%) . | |
|---|---|---|---|---|
| deceased n = 14 (8%) . | dropout (non-death-related) n = 18 (10%) . | |||
| Time since t1 in months . | . | . | . | . |
| Mean (SD, Min–Max) | 5.34 (2.5, 1.4–13.8) | 5.31 (2.6, 1.4–1.3) | 5.62 (3.7, 1.6–13.8) | 5.03 (0.0, 5.0–5.0) |
| Median, Q1–Q3 | 5.0 (3.2–6.2) | 4.8 (3.1–6.7) | 3.7 (2.9–9.0) | 5.0 (5.0–5.0) |
| Age in years* | ||||
| Mean (SD, Min–Max) | 51 (14, 21–78) | 50 (14, 21–78) | 62 (12, 37–76) | 51 (13, 29–75) |
| Sex n (%) | ||||
| male | 92 (53) | 72 (51) | 8 (57) | 12 (67) |
| female | 81 (47) | 69 (49) | 6 (43) | 6 (33) |
| Living situation*, n (%) | ||||
| single | 39 (22) | 30 (21) | 2 (14) | 7 (39) |
| in relationship | 124 (72) | 102 (72) | 12 (86) | 10 (56) |
| unknown | 10 (7) | 9 (7) | - | 1 (5) |
| WHO grade*, n (%) | ||||
| LGG (WHO I and II) | 32 (19) | 26 (18) | - | 6 (33) |
| HGG (WHO III and IV) | 141 (81) | 115 (82) | 14 (100) | 12 (67) |
| Tumor localization I*, n (%) | ||||
| frontal | 75 (43) | 68 (48) | 3 (21) | 4 (22) |
| temporal | 48 (28) | 38 (27) | 7 (50) | 3 (17) |
| parietal | 23 (13) | 18 (13) | 3 (21) | 2 (11) |
| occipital | 12 (7) | 6 (4) | 1 (7) | 5 (28) |
| other | 15 (9) | 11 (8) | - | 4 (22) |
| Tumor localization II *, n (%) | ||||
| eloquent | 87 (50) | 71 (50) | 8 (57) | 8 (44) |
| non eloquent | 85 (49) | 69 (49) | 6 (43) | 10 (56) |
| n.a. | 1 (1) | 1 (1) | - | - |
| Extent of resection, n (%) | ||||
| subtotal resection/biopsy | 68 (39) | 55 (39) | 10 (71) | 3 (17) |
| complete resection | 102 (59) | 83 (59) | 4 (29) | 15 (83) |
| n.a. | 3 (2) | 3 (2) | - | - |
| Ongoing chemotherapy*, n (%) | ||||
| yes | 63 (36) | 44 (31) | 11 (79) | 8 (44) |
| no | 110 (64) | 97 (69) | 3 (21) | 10 (56) |
| Surgery for recurrent tumor*, n (%) | ||||
| yes | 56 (32) | 45 (32) | 6 (43) | 5 (28) |
| no | 117 (68) | 96 (68) | 8 (57) | 13 (72) |
| Karnofsky Peformance Status (KPS)* | ||||
| Median (SD, range) | 90 (40–100) | 90 (40–100) | 70 (60–90) | 90 (10–100) |
| KPS < 70, n (%) | 18 (10.4) | 7 (5.0) | 4 (22.2) | 7 (50.0) |
| KPS ≥ 70, n (%) | 151 (87.3) | 130 (92.2) | 14 (77.8) | 7 (50.0) |
| n.a. | 4 (2.3) | 4 (2.8) | - | - |
| Time since diagnosis in months* | ||||
| Mean (SD, range) | 46 (49, 2–278) | 52 (54, 28–279) | 31 (41, 2–125) | 60 (55, 4–173) |
| Median, Q1–Q3 | 34 (10–70) | 35 (14–69) | 13 (8–34) | 47 (7–95) |
| < 3 years, n (%) | 89 (51) | 71 (50) | 11 (79) | 7 (39) |
| ≥ 3 years, n (%) | 76 (44) | 65 (46) | 3 (21) | 8 (44) |
| n.a. | 8 (5) | 5 (4) | - | 3 (17) |
| Value of Distress Thermometer* | ||||
| Mean (SD, range) | 4.6 (2.7; 0.0–10.0) | 4.6 (2.8; 0.0–10.0) | 5.2 (2.3; 0.0–9.0) | 4.4 (2.5; 0.0–8.0) |
| < 6 (n, %) | 109 (63) | 88 (62) | 9 (64) | 12 (67) |
| ≥ 6 (n, %) | 57 (33) | 46 (33) | 5 (36) | 6 (33) |
| n.a. | 7 (4) | 7 (5) | - | - |
| Selected EORTC-QLQ-C30 and EORTC-QLQ-BN20 Scores*, Mean (SD) | ||||
| C30 Global Health Status/QoL | 61.0 (22.7) | 62.1 (23.0) | 54.2 (22.3) | 57.9 (20.9) |
| C30 Physical functioning | 74.7 (25.6) | 77.1 (24.8) | 56.2 (28.8) | 70.4 (24.2) |
| C30 Emotional functioning | 59.4 (27.4) | 59.3 (28.2) | 59.5 (23.3) | 60.3 (24.9) |
| C30 Cognitive functioning | 63.0 (32.5) | 64.0 (32.5) | 50.0 (33.3) | 65.7 (31.4) |
| BN20 Future uncertainty | 39.3 (29.2) | 38.8 (29.9) | 38.8 (25.9) | 43.8 (27.3) |
| BN20 Motor dysfunction | 25.0 (27.2) | 21.6 (26.1) | 42.9 (31.4) | 36.4 (25.2) |
| SCNS-SF34G Scores* | ||||
| Physical and daily living needs Mean (SD) | 19.2 (21.4; 0.0–83.3) | 19.8 (22.7) | 14.7 (13.9) | 18.1 (14.8) |
| Median (Q1 – Q3) | 12.5 (0.0–25.0) | 12.5 (0–29.2) | 12.5 (4.2–22.9) | 16.7 (7.3–26.0) |
| Psychological needs Mean (SD) | 26.9 (27.8; 0.0–95.0) | 27.4 (28.6) | 25.7 (27.9) | 24.3 (22.8) |
| Median (Q1 – Q3) | 17.5 (5.0–45.0) | 17.5 (5.0–46.3) | 12.5 (1.3–48.8) | 11.3 (5.0–45.0) |
| Patient care and support needs Mean (SD) | 10.5 (19.1; 0.0–93.8) | 10.2 (18.3) | 10.7 (24.3) | 13.0 (21.7) |
| Median (Q1 – Q3) | 0.0 (0.0–12.5) | 0.0 (0–12.5) | 0.0 (0.0–10.9) | 0.0 (0.0–21.9) |
| Health system and information needs Mean (SD) | 22.1 (27.3; 0.0–100.0) | 22.2 (27.4) | 13.5 (19.8) | 27.0 (30.7) |
| Median (Q1 – Q3) | 11.4 (0.0–36.4) | 11.0 (0.0–36.4) | 4.5 (2.3–19.3) | 15.9 (0.0–53.3) |
| Sexuality needs Mean (SD) | 13.4 (21.8; 0.0–100.0) | 14.6 (22.5) | 5.8 (14.2) | 9.8 (21.1) |
| Median (Q1 – Q3) | 0.0 (0.0–16.7) | 0.0 (0.0–25.0) | 0.0 (0.0–4.2) | 0.0 (0.0–12.5) |
*Socio-demographic/clinical status information and results of questionnaires at t1
1Time to t2
2Time until death
3Time until drop out, censored after 5 months
4Time to event (t2/Death/Censoring)
HGG, high-grade glioma; LGG, low-grade glioma
Clinical and demographic data of the patient sample (participants and dropouts are shown separately) and results of psychosocial assessment using the Distress Thermometer, the EORTC-QLQ-C30 and EORTC-QLQ-BN20, and the SCNS SF34-G at t1 are displayed
| . | Total study sample (t1) n = 173 (100%) . | Patients with complete follow-up (t1 and t2) n = 141 (82%) . | Patients without follow-up (no t2) n = 32 (19%) . | |
|---|---|---|---|---|
| deceased n = 14 (8%) . | dropout (non-death-related) n = 18 (10%) . | |||
| Time since t1 in months . | . | . | . | . |
| Mean (SD, Min–Max) | 5.34 (2.5, 1.4–13.8) | 5.31 (2.6, 1.4–1.3) | 5.62 (3.7, 1.6–13.8) | 5.03 (0.0, 5.0–5.0) |
| Median, Q1–Q3 | 5.0 (3.2–6.2) | 4.8 (3.1–6.7) | 3.7 (2.9–9.0) | 5.0 (5.0–5.0) |
| Age in years* | ||||
| Mean (SD, Min–Max) | 51 (14, 21–78) | 50 (14, 21–78) | 62 (12, 37–76) | 51 (13, 29–75) |
| Sex n (%) | ||||
| male | 92 (53) | 72 (51) | 8 (57) | 12 (67) |
| female | 81 (47) | 69 (49) | 6 (43) | 6 (33) |
| Living situation*, n (%) | ||||
| single | 39 (22) | 30 (21) | 2 (14) | 7 (39) |
| in relationship | 124 (72) | 102 (72) | 12 (86) | 10 (56) |
| unknown | 10 (7) | 9 (7) | - | 1 (5) |
| WHO grade*, n (%) | ||||
| LGG (WHO I and II) | 32 (19) | 26 (18) | - | 6 (33) |
| HGG (WHO III and IV) | 141 (81) | 115 (82) | 14 (100) | 12 (67) |
| Tumor localization I*, n (%) | ||||
| frontal | 75 (43) | 68 (48) | 3 (21) | 4 (22) |
| temporal | 48 (28) | 38 (27) | 7 (50) | 3 (17) |
| parietal | 23 (13) | 18 (13) | 3 (21) | 2 (11) |
| occipital | 12 (7) | 6 (4) | 1 (7) | 5 (28) |
| other | 15 (9) | 11 (8) | - | 4 (22) |
| Tumor localization II *, n (%) | ||||
| eloquent | 87 (50) | 71 (50) | 8 (57) | 8 (44) |
| non eloquent | 85 (49) | 69 (49) | 6 (43) | 10 (56) |
| n.a. | 1 (1) | 1 (1) | - | - |
| Extent of resection, n (%) | ||||
| subtotal resection/biopsy | 68 (39) | 55 (39) | 10 (71) | 3 (17) |
| complete resection | 102 (59) | 83 (59) | 4 (29) | 15 (83) |
| n.a. | 3 (2) | 3 (2) | - | - |
| Ongoing chemotherapy*, n (%) | ||||
| yes | 63 (36) | 44 (31) | 11 (79) | 8 (44) |
| no | 110 (64) | 97 (69) | 3 (21) | 10 (56) |
| Surgery for recurrent tumor*, n (%) | ||||
| yes | 56 (32) | 45 (32) | 6 (43) | 5 (28) |
| no | 117 (68) | 96 (68) | 8 (57) | 13 (72) |
| Karnofsky Peformance Status (KPS)* | ||||
| Median (SD, range) | 90 (40–100) | 90 (40–100) | 70 (60–90) | 90 (10–100) |
| KPS < 70, n (%) | 18 (10.4) | 7 (5.0) | 4 (22.2) | 7 (50.0) |
| KPS ≥ 70, n (%) | 151 (87.3) | 130 (92.2) | 14 (77.8) | 7 (50.0) |
| n.a. | 4 (2.3) | 4 (2.8) | - | - |
| Time since diagnosis in months* | ||||
| Mean (SD, range) | 46 (49, 2–278) | 52 (54, 28–279) | 31 (41, 2–125) | 60 (55, 4–173) |
| Median, Q1–Q3 | 34 (10–70) | 35 (14–69) | 13 (8–34) | 47 (7–95) |
| < 3 years, n (%) | 89 (51) | 71 (50) | 11 (79) | 7 (39) |
| ≥ 3 years, n (%) | 76 (44) | 65 (46) | 3 (21) | 8 (44) |
| n.a. | 8 (5) | 5 (4) | - | 3 (17) |
| Value of Distress Thermometer* | ||||
| Mean (SD, range) | 4.6 (2.7; 0.0–10.0) | 4.6 (2.8; 0.0–10.0) | 5.2 (2.3; 0.0–9.0) | 4.4 (2.5; 0.0–8.0) |
| < 6 (n, %) | 109 (63) | 88 (62) | 9 (64) | 12 (67) |
| ≥ 6 (n, %) | 57 (33) | 46 (33) | 5 (36) | 6 (33) |
| n.a. | 7 (4) | 7 (5) | - | - |
| Selected EORTC-QLQ-C30 and EORTC-QLQ-BN20 Scores*, Mean (SD) | ||||
| C30 Global Health Status/QoL | 61.0 (22.7) | 62.1 (23.0) | 54.2 (22.3) | 57.9 (20.9) |
| C30 Physical functioning | 74.7 (25.6) | 77.1 (24.8) | 56.2 (28.8) | 70.4 (24.2) |
| C30 Emotional functioning | 59.4 (27.4) | 59.3 (28.2) | 59.5 (23.3) | 60.3 (24.9) |
| C30 Cognitive functioning | 63.0 (32.5) | 64.0 (32.5) | 50.0 (33.3) | 65.7 (31.4) |
| BN20 Future uncertainty | 39.3 (29.2) | 38.8 (29.9) | 38.8 (25.9) | 43.8 (27.3) |
| BN20 Motor dysfunction | 25.0 (27.2) | 21.6 (26.1) | 42.9 (31.4) | 36.4 (25.2) |
| SCNS-SF34G Scores* | ||||
| Physical and daily living needs Mean (SD) | 19.2 (21.4; 0.0–83.3) | 19.8 (22.7) | 14.7 (13.9) | 18.1 (14.8) |
| Median (Q1 – Q3) | 12.5 (0.0–25.0) | 12.5 (0–29.2) | 12.5 (4.2–22.9) | 16.7 (7.3–26.0) |
| Psychological needs Mean (SD) | 26.9 (27.8; 0.0–95.0) | 27.4 (28.6) | 25.7 (27.9) | 24.3 (22.8) |
| Median (Q1 – Q3) | 17.5 (5.0–45.0) | 17.5 (5.0–46.3) | 12.5 (1.3–48.8) | 11.3 (5.0–45.0) |
| Patient care and support needs Mean (SD) | 10.5 (19.1; 0.0–93.8) | 10.2 (18.3) | 10.7 (24.3) | 13.0 (21.7) |
| Median (Q1 – Q3) | 0.0 (0.0–12.5) | 0.0 (0–12.5) | 0.0 (0.0–10.9) | 0.0 (0.0–21.9) |
| Health system and information needs Mean (SD) | 22.1 (27.3; 0.0–100.0) | 22.2 (27.4) | 13.5 (19.8) | 27.0 (30.7) |
| Median (Q1 – Q3) | 11.4 (0.0–36.4) | 11.0 (0.0–36.4) | 4.5 (2.3–19.3) | 15.9 (0.0–53.3) |
| Sexuality needs Mean (SD) | 13.4 (21.8; 0.0–100.0) | 14.6 (22.5) | 5.8 (14.2) | 9.8 (21.1) |
| Median (Q1 – Q3) | 0.0 (0.0–16.7) | 0.0 (0.0–25.0) | 0.0 (0.0–4.2) | 0.0 (0.0–12.5) |
| . | Total study sample (t1) n = 173 (100%) . | Patients with complete follow-up (t1 and t2) n = 141 (82%) . | Patients without follow-up (no t2) n = 32 (19%) . | |
|---|---|---|---|---|
| deceased n = 14 (8%) . | dropout (non-death-related) n = 18 (10%) . | |||
| Time since t1 in months . | . | . | . | . |
| Mean (SD, Min–Max) | 5.34 (2.5, 1.4–13.8) | 5.31 (2.6, 1.4–1.3) | 5.62 (3.7, 1.6–13.8) | 5.03 (0.0, 5.0–5.0) |
| Median, Q1–Q3 | 5.0 (3.2–6.2) | 4.8 (3.1–6.7) | 3.7 (2.9–9.0) | 5.0 (5.0–5.0) |
| Age in years* | ||||
| Mean (SD, Min–Max) | 51 (14, 21–78) | 50 (14, 21–78) | 62 (12, 37–76) | 51 (13, 29–75) |
| Sex n (%) | ||||
| male | 92 (53) | 72 (51) | 8 (57) | 12 (67) |
| female | 81 (47) | 69 (49) | 6 (43) | 6 (33) |
| Living situation*, n (%) | ||||
| single | 39 (22) | 30 (21) | 2 (14) | 7 (39) |
| in relationship | 124 (72) | 102 (72) | 12 (86) | 10 (56) |
| unknown | 10 (7) | 9 (7) | - | 1 (5) |
| WHO grade*, n (%) | ||||
| LGG (WHO I and II) | 32 (19) | 26 (18) | - | 6 (33) |
| HGG (WHO III and IV) | 141 (81) | 115 (82) | 14 (100) | 12 (67) |
| Tumor localization I*, n (%) | ||||
| frontal | 75 (43) | 68 (48) | 3 (21) | 4 (22) |
| temporal | 48 (28) | 38 (27) | 7 (50) | 3 (17) |
| parietal | 23 (13) | 18 (13) | 3 (21) | 2 (11) |
| occipital | 12 (7) | 6 (4) | 1 (7) | 5 (28) |
| other | 15 (9) | 11 (8) | - | 4 (22) |
| Tumor localization II *, n (%) | ||||
| eloquent | 87 (50) | 71 (50) | 8 (57) | 8 (44) |
| non eloquent | 85 (49) | 69 (49) | 6 (43) | 10 (56) |
| n.a. | 1 (1) | 1 (1) | - | - |
| Extent of resection, n (%) | ||||
| subtotal resection/biopsy | 68 (39) | 55 (39) | 10 (71) | 3 (17) |
| complete resection | 102 (59) | 83 (59) | 4 (29) | 15 (83) |
| n.a. | 3 (2) | 3 (2) | - | - |
| Ongoing chemotherapy*, n (%) | ||||
| yes | 63 (36) | 44 (31) | 11 (79) | 8 (44) |
| no | 110 (64) | 97 (69) | 3 (21) | 10 (56) |
| Surgery for recurrent tumor*, n (%) | ||||
| yes | 56 (32) | 45 (32) | 6 (43) | 5 (28) |
| no | 117 (68) | 96 (68) | 8 (57) | 13 (72) |
| Karnofsky Peformance Status (KPS)* | ||||
| Median (SD, range) | 90 (40–100) | 90 (40–100) | 70 (60–90) | 90 (10–100) |
| KPS < 70, n (%) | 18 (10.4) | 7 (5.0) | 4 (22.2) | 7 (50.0) |
| KPS ≥ 70, n (%) | 151 (87.3) | 130 (92.2) | 14 (77.8) | 7 (50.0) |
| n.a. | 4 (2.3) | 4 (2.8) | - | - |
| Time since diagnosis in months* | ||||
| Mean (SD, range) | 46 (49, 2–278) | 52 (54, 28–279) | 31 (41, 2–125) | 60 (55, 4–173) |
| Median, Q1–Q3 | 34 (10–70) | 35 (14–69) | 13 (8–34) | 47 (7–95) |
| < 3 years, n (%) | 89 (51) | 71 (50) | 11 (79) | 7 (39) |
| ≥ 3 years, n (%) | 76 (44) | 65 (46) | 3 (21) | 8 (44) |
| n.a. | 8 (5) | 5 (4) | - | 3 (17) |
| Value of Distress Thermometer* | ||||
| Mean (SD, range) | 4.6 (2.7; 0.0–10.0) | 4.6 (2.8; 0.0–10.0) | 5.2 (2.3; 0.0–9.0) | 4.4 (2.5; 0.0–8.0) |
| < 6 (n, %) | 109 (63) | 88 (62) | 9 (64) | 12 (67) |
| ≥ 6 (n, %) | 57 (33) | 46 (33) | 5 (36) | 6 (33) |
| n.a. | 7 (4) | 7 (5) | - | - |
| Selected EORTC-QLQ-C30 and EORTC-QLQ-BN20 Scores*, Mean (SD) | ||||
| C30 Global Health Status/QoL | 61.0 (22.7) | 62.1 (23.0) | 54.2 (22.3) | 57.9 (20.9) |
| C30 Physical functioning | 74.7 (25.6) | 77.1 (24.8) | 56.2 (28.8) | 70.4 (24.2) |
| C30 Emotional functioning | 59.4 (27.4) | 59.3 (28.2) | 59.5 (23.3) | 60.3 (24.9) |
| C30 Cognitive functioning | 63.0 (32.5) | 64.0 (32.5) | 50.0 (33.3) | 65.7 (31.4) |
| BN20 Future uncertainty | 39.3 (29.2) | 38.8 (29.9) | 38.8 (25.9) | 43.8 (27.3) |
| BN20 Motor dysfunction | 25.0 (27.2) | 21.6 (26.1) | 42.9 (31.4) | 36.4 (25.2) |
| SCNS-SF34G Scores* | ||||
| Physical and daily living needs Mean (SD) | 19.2 (21.4; 0.0–83.3) | 19.8 (22.7) | 14.7 (13.9) | 18.1 (14.8) |
| Median (Q1 – Q3) | 12.5 (0.0–25.0) | 12.5 (0–29.2) | 12.5 (4.2–22.9) | 16.7 (7.3–26.0) |
| Psychological needs Mean (SD) | 26.9 (27.8; 0.0–95.0) | 27.4 (28.6) | 25.7 (27.9) | 24.3 (22.8) |
| Median (Q1 – Q3) | 17.5 (5.0–45.0) | 17.5 (5.0–46.3) | 12.5 (1.3–48.8) | 11.3 (5.0–45.0) |
| Patient care and support needs Mean (SD) | 10.5 (19.1; 0.0–93.8) | 10.2 (18.3) | 10.7 (24.3) | 13.0 (21.7) |
| Median (Q1 – Q3) | 0.0 (0.0–12.5) | 0.0 (0–12.5) | 0.0 (0.0–10.9) | 0.0 (0.0–21.9) |
| Health system and information needs Mean (SD) | 22.1 (27.3; 0.0–100.0) | 22.2 (27.4) | 13.5 (19.8) | 27.0 (30.7) |
| Median (Q1 – Q3) | 11.4 (0.0–36.4) | 11.0 (0.0–36.4) | 4.5 (2.3–19.3) | 15.9 (0.0–53.3) |
| Sexuality needs Mean (SD) | 13.4 (21.8; 0.0–100.0) | 14.6 (22.5) | 5.8 (14.2) | 9.8 (21.1) |
| Median (Q1 – Q3) | 0.0 (0.0–16.7) | 0.0 (0.0–25.0) | 0.0 (0.0–4.2) | 0.0 (0.0–12.5) |
*Socio-demographic/clinical status information and results of questionnaires at t1
1Time to t2
2Time until death
3Time until drop out, censored after 5 months
4Time to event (t2/Death/Censoring)
HGG, high-grade glioma; LGG, low-grade glioma
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
